Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofacitinib - Pfizer

Drug Profile

Tofacitinib - Pfizer

Alternative Names: Cp-690,550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Xeljanz; Xeljanz XR

Latest Information Update: 22 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Johns Hopkins University; Pfizer; University of Michigan
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis; Ulcerative colitis
  • Registered Psoriatic arthritis
  • Phase III Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis
  • Phase II Atopic dermatitis
  • Phase I/II Diffuse scleroderma
  • Phase I Dermatomyositis
  • Discontinued Asthma; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection

Most Recent Events

  • 19 Oct 2018 Interim efficacy data from a phase I trial in dermatomyositis presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
  • 19 Oct 2018 Pfizer and Johns Hopkins University completes enrolment in its phase I STIR trial for dermatomyositis in USA (PO)
  • 10 Aug 2018 Phase-III clinical trials in Psoriatic arthritis in China (PO) (NCT03486457)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top